Neuland Laboratories share news and announcements
NSE: NEULANDLABBSE: 524558Pharmaceuticals & BiotechnologySmall Cap
Last close ₹18,865.00down ₹70.00 (0.37%)BSE ₹18,924.25
Share price at the NSE close on 23 Oct 2026. Previous close ₹18,935.00.
52-week range of traded prices to 23 Oct 2026
₹11,500.00Low, 23 Mar 2026₹24,225.00High, 9 Sep 2026
- Next results date: the board meets on 3 Nov 2026 to consider: financial results.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹24,204 Cr356th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 5 Aug 2026
- 48.6
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 12 May 2026
- 12.9
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.18%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 5 Aug 2026
- 29.3%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 5 Aug 2026
- 32.1%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 12 May 2026
- 0.10
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 53,34748.3% delivered
Neuland Laboratories board and management
35 filed, newest first.
May 2025
15 May · Management
Mar 2025
10 Mar · Management
Jan 2025
May 2024
8 May · Management
Mar 2024
31 Mar · Management
6 Mar · Management
Jan 2024
6 Jan · Management
Nov 2023
22 Nov · Management
6 Nov · Management
Sep 2023
25 Sep · Management
Jun 2023
27 Jun · Management
Nov 2022
Oct 2022
Sep 2022
Feb 2020
May 2019
17 May · Management
Nov 2017
Aug 2017
Feb 2017
Dec 2014
Aug 2014
May 2014
Mar 2014
20 Mar · Management
Board of Directors had at its meeting held on March 20, 2014 approved re-appointment of Dr.D.R.Rao as the Chairman and Managing Director of the Company, for a further period of 5 years w.e.f. April 01, 2014 subject to the approval of the shareholders.
May 2013
10 May · Management
Board of Directors of the Company at its meeting held on May 10, 2013 has approved reappointment of Mr. D. Sucheth Rao, as the Whole Time Director and Chief Executive Officer of the Company for a period of (5) Five years with effect from August 1, 2013, subject to the approval of shareholders in ensuing Annual General Meeting.
May 2012
3 May · Management
Board of Directors of the Company at its meeting held on May 03, 2012 have approved reappointment of Mr. D. Saharsh Rao, as the Whole Time Director and President - Contract Research of the Company for a period of (3) three years with effect from June 01, 2012, subject to the approval of shareholders in ensuing Annual General Meeting.
Jan 2012
6 Jan · Management
Ms.Sarada Bhamidipati has been appointed as Company Secretary and Compliance Officer of the company w.e.f. January 03, 2012.
May 2011
23 May · Management
Export Import Bank of India (EXIM Bank) has withdrawn the nomination of Ms. Daya Chandrahas and has appointed Mr. Nadeem Panjetan as their Nominee Director on the Board of the Company with effect from April 29, 2011.
Apr 2011
20 Apr · Management
Ms.Mary Monica Braganza has been appointed as Company Secretary and Compliance Officer of the Company w.e.f. April 18, 2011.
Mar 2011
10 Mar · Management
Ms. Deepika Gupta has resigned from the position of Company Secretary and Compliance Officer and relieved from her services w.e.f. March 10, 2011. Mr.N.S. Viswanathan, Vice President-Finance will be acting as Compliance Officer of the Company w.e.f. March 10, 2011 onwards consequent to resignation of Ms.Deepika Gupta.
Aug 2010
2 Aug · Management
Shareholders at the Annual General Meeting of the Company held on July 29, 2010, passed the following resolutions with requisite majority : (1) Appointed Mr. H. Dhanrajgir, as Director retiring by rotation; (2) Appointed Mr. P.V. Maiya, as Director retiring by rotation; (3) Appointed M/s. K S Aiyar & Co., as Auditors for the year ending March 31, 2011; (4) Appointed Dr. Cristopher M. Cimarusti as Director, liable to retire by rotation; (5) Re-appointed Dr. D.R.Rao as Chairman and Managing Director of the Company for a period of 5 years w.e.f. April 01, 2009.
May 2010
29 May · Management
Board of Directors in their meeting held on May 29, 2010 have approved reappointment of Dr. D. R. Rao, as the Chairman and Managing Director of the Company for the period of (5) five years with effect from April 1, 2009 subject to the approval of shareholders in ensuing Annual General Meeting.
Jun 2009
17 Jun · Management
Ms. Deepika Gupta has joined us as Company Secretary on 13th May 2009 and she will also act as compliance officer of the Company from 13th May 2009 onwards in place of Mr. A. Raghvendracharyulu
Apr 2009
9 Apr · Management
Ms. K. Sandhya Lakshmi has resigned from the position of Company Secretary and relieved from her services w.e.f. 02.04.2009